S
Salomon M. Stemmer
Researcher at Rabin Medical Center
Publications - 215
Citations - 12740
Salomon M. Stemmer is an academic researcher from Rabin Medical Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 43, co-authored 189 publications receiving 9651 citations. Previous affiliations of Salomon M. Stemmer include University of New South Wales & Tel Aviv University.
Papers
More filters
Journal ArticleDOI
A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC)
Manuel Hidalgo,Ron Epelbaum,Brian M. Wolpin,Salomon M. Stemmer,Ravit Geva,Talia Golan,Erkut Borazanci,Mitesh J. Borad,Katrina S. Pedersen,J.O. Park,Robert A. Ramirez,Amnon Peled,Tzipora M. Lustig,O. Bohana Kashtan,O. Rosenfeld,Ella Sorani,Katia Schlienger,A. Vainstein Haras,D. D. Von Hoff +18 more
Journal ArticleDOI
Chemotherapy-induced ovarian failure in young breast cancer patients: The role of vascular toxicity.
Irit Ben-Aharon,Tal Granot,Israel Meizner,Shulamith Rizel,Rinat Yerushalmi,Aaron Sulkes,Salomon M. Stemmer +6 more
TL;DR: The continuous prospective evaluation of ovarian function in this cohort of young breast cancer patients undergoing adjuvant/neoadjuvant chemotherapy found that ovarian blood flow was significantly reduced immediately following chemotherapy and after treatment.
Journal ArticleDOI
Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
Erez Bar-Haim,Noa Eliakim-Raz,Amos Stemmer,Hila Cohen,Uri Elia,Asaf Ness,Muhammad Awwad,N. Ghantous,Neta Moskovits,Shahar Rotem,Salomon M. Stemmer +10 more
TL;DR: The high response following the third administration questions the necessity of an early fourth boost in elderly people immunized with three vaccine doses of BNT162b2.
Journal ArticleDOI
Adjuvant Docetaxel and Cyclophosphamide (DC) with Prophylactic Granulocyte Colony-Stimulating Factor (G-CSF) on Days 8 &12 in Breast Cancer Patients: A Retrospective Analysis
Rinat Yerushalmi,Hadar Goldvaser,Aaron Sulkes,Irit Ben-Aharon,Daniel Hendler,Victoria Neiman,Noa Beatrice Ciuraru,Luisa Bonilla,Limor Amit,Alona Zer,Tal Granot,Shulamith Rizel,Salomon M. Stemmer +12 more
TL;DR: Primary prophylactic G-CSF support on days 8 and 12 of the cycle provides a tolerable option to deliver the DC protocol, and is in line with other retrospective protocols using longer schedules of GF support.
Journal ArticleDOI
Phase 2 single arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi Sarcoma (cKS).
Alona Zer,Oded Icht,Laviv Yosef,D R Avram,Oded Jacobi,Eyal Fenig,N. Kurman,Idit Peretz,Sivan Shamai,Ofer Merimsky,E. Ben-Ami,R. Shapira Frommer,A. E. Schwarzbach,Hanna Bernstine,Rony Weitzen,Olga Vornicova,G. Bar-Sela,Salomon M. Stemmer,Michal Lotem +18 more
TL;DR: In this paper , the efficacy and safety of nivolumab in combination with ipilimumab in patients with previously treated progressive Kaposi sarcoma (cKS) were evaluated.